/GLSHQ

GLSHQ Stock - Gelesis Holdings, Inc.

Q: What is the analyst price target for GLSHQ?

Analyst price target information is not currently available for GLSHQ.

Q: What is GLSHQ's market cap?

Market capitalization information is not currently available for GLSHQ.

Healthcare|Biotechnology|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for GLSHQ

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.67

52W High$0.01

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020
Revenue	$25.77M	$11.19M	N/A
Gross Profit	$-1,791,000	$1.20M	N/A
Gross Margin	-7.0%	10.7%	N/A
Operating Income	$-121,806,000	$-84,973,000	N/A
Net Income	$-57,128,000	$-93,723,000	$-15,294,860
Net Margin	-221.7%	-837.9%	N/A
EPS	$-1.35	$-16.41	$-0.44

Company Overview

Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation. Further, it develops pre-clinical product GS300 for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Gelesis Holdings, Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts. On October 30, 2023, Gelesis Holdings, Inc., along its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

Visit Website

Earnings History & Surprises

GLSHQ

Beat Rate

25%

Last 4 quarters

Avg Surprise

-12.9%

EPS vs Estimate

Beats / Misses

1/3

Last 12 quarters

Latest EPS

$-0.10

Q2 2023

EPS Surprise History

Q3 21

No data

Q4 21

No data

Q1 22

No data

Q2 22

+49.0%

$-0.17vs$-0.34

Q3 22

No data

Q4 22

-26.2%

$-0.33vs$-0.27

Q1 23

-13.3%

$-0.07vs$-0.06

Q2 23

-61.2%

$-0.10vs$-0.06

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2025	Apr 4, 2025	—	—	—	—
Q1 2025	Mar 28, 2025	—	—	—	—
Q4 2024	Dec 26, 2024	—	—	—	—
Q3 2024	Sep 26, 2024	—	—	—	—
Q2 2024	May 10, 2024	—	—	—	—
Q1 2024	Feb 12, 2024	—	—	—	—
Q4 2023	Dec 28, 2023	$-0.07	—	—	—
Q2 2023	Jun 30, 2023	$-0.06	$-0.10	-61.2%	✗ MISS
Q1 2023	Mar 31, 2023	$-0.06	$-0.07	-13.3%	✗ MISS
Q4 2022	Dec 31, 2022	$-0.27	$-0.33	-26.2%	✗ MISS
Q3 2022	Sep 30, 2022	—	$-0.20	—	—
Q2 2022	Jun 30, 2022	$-0.34	$-0.17	+49.0%	✓ BEAT
Q1 2022	Mar 31, 2022	—	$-0.09	—	—
Q4 2021	Dec 31, 2021	—	$-0.27	—	—
Q3 2021	Sep 30, 2021	—	$-5.40	—	—
Q2 2021	Jun 30, 2021	—	$-4.35	—	—
Q1 2021	Mar 31, 2021	—	$-3.27	—	—
Q4 2020	Dec 30, 2020	—	$-0.44	—	—